Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical
The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical resection for hepatocellular carcinoma. The main questions it aims to answer are:
Is hydrodissection-assisted microwave ablation safe and effective for treating hepatocellular carcinoma? How does the therapeutic effect of hydrodissection-assisted microwave ablation compare with surgical resection for hepatocellular carcinoma? Patients who receive either microwave ablation or surgical resection will Undergo a 2-year follow-up period.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:dezhi Zhang Associate Chief Physician, MD
- 电话号码:+8618186876068
- 邮箱:dezhi@jlu.edu.cn
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:Patients with Child-Pugh grade A or B liver function.Single hepatic lesion with a maximum diameter ≤ 5 cm.The lesion is located in the subphrenic region with a distance ≤ 10 mm from the right diaphragm.
Exclusion Criteria:Presence of extrahepatic metastasis or other concomitant malignant tumors.Presence of severe cardiac, pulmonary, or renal dysfunction.Platelet count < 50×10⁹/L with irreversible coagulation disorders. Patients with incomplete imaging or clinical medical data.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Hydrodissection-assisted microwave ablation cohort
Patients with hepatocellular carcinoma receiving hydrodissection-assisted microwave ablation under routine clinical care.
No study-specific intervention will be assigned by researchers.
|
For subphrenic hepatocellular carcinoma treated with microwave ablation, ultrasound-guided injection of normal saline into the diaphragm is performed during ablation to establish a hydrodissection barrier and optimise lesion visualisation.
|
|
Surgical resection cohort
Patients with hepatocellular carcinoma receiving surgical resection under routine clinical care.
No study-specific intervention will be assigned by researchers.
|
Patients with subphrenic hepatocellular carcinoma who undergo surgical resection are managed according to clinical diagnostic and therapeutic standards for hepatocellular carcinoma.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS)
大体时间:Up to 2 years after treatment
|
the time from initiation of treatment to disease progression or death.
|
Up to 2 years after treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall survival (OS)
大体时间:Up to 2 years after treatment
|
the time from initiation of treatment to death, loss to follow-up, or last follow-up.
|
Up to 2 years after treatment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.